[177Lu]Lu-LNC1010用于鼻咽癌肽受体放射性核素治疗的研发
本研究基于DOTATATE开发了长效SSTR2类似物LNC1010,在C666-1鼻咽癌细胞和荷瘤鼠中比较[68Ga]Ga/[177Lu]Lu-LNC1010与[68Ga]Ga/[177Lu]Lu-DOTATATE的显像与治疗效能,并在1例转移性鼻咽癌患者中开展概念验证。结果显示LNC1010在临床前研究中肿瘤摄取更高、滞留更久、抑瘤效果优于DOTATATE,该患者治疗有效且副作用可忽略。
要点
- LNC1010在C666-1鼻咽癌细胞中对SSTR2有强摄取和特异性亲和力。
- 荷瘤鼠中[68Ga]Ga/[177Lu]Lu-LNC1010的肿瘤摄取和滞留均高于[68Ga]Ga/[177Lu]Lu-DOTATATE。
- 临床前PRRT中[177Lu]Lu-LNC1010抑瘤效果优于[177Lu]Lu-DOTATATE,1例患者治疗有效且副作用可忽略。
核心结论
- [177Lu]Lu-LNC1010在SSTR2阳性鼻咽癌中肿瘤摄取增加、滞留延长,临床前研究中抗肿瘤效能优于[177Lu]Lu-DOTATATE。
- 这些发现提示[177Lu]Lu-LNC1010的PRRT是晚期鼻咽癌有前景的治疗方法,将PRRT的临床范围扩展到神经内分泌肿瘤之外。
研究设计与样本
- 体外用C666-1鼻咽癌细胞评估LNC1010的结合特性。
- 在C666-1鼻咽癌荷瘤鼠中通过PET和SPECT显像、生物分布研究和PRRT评估[68Ga]Ga/[177Lu]Lu-LNC1010的体内药代动力学,并与[68Ga]Ga/[177Lu]Lu-DOTATATE比较。
- 在1例转移性鼻咽癌患者中开展显像与治疗的概念验证。
主要发现
- LNC1010在C666-1鼻咽癌细胞中表现出对SSTR2的强摄取和特异性亲和力。
- PET和SPECT显像显示[68Ga]Ga/[177Lu]Lu-LNC1010在C666-1荷瘤鼠中的摄取高于[68Ga]Ga/[177Lu]Lu-DOTATATE,肿瘤滞留时间更长。
- 生物分布研究证实[177Lu]Lu-LNC1010的摄取高于[177Lu]Lu-DOTATATE且滞留延长。
- 临床前PRRT研究中,[177Lu]Lu-LNC1010对C666-1荷瘤鼠肿瘤生长的抑制大于[177Lu]Lu-DOTATATE。
- 在随后的初步临床研究中,[177Lu]Lu-LNC1010的PRRT在1例转移性鼻咽癌患者中取得良好疗效且副作用可忽略。
局限性
- 初步临床研究仅纳入1例转移性鼻咽癌患者。
- 作者称这些发现提示[177Lu]Lu-LNC1010的PRRT是晚期鼻咽癌有前景的治疗方法,属探索性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Somatostatin Receptor 2 (SSTR2)-targeted radiopharmaceutical [68Ga]Ga-DOTATATE has potential advantages in the diagnosis of nasopharyngeal carcinoma (NPC). This study introduces a novel long-lasting SSTR2 analogue, LNC1010, based on DOTATATE, a truncated Evans blue-binding moiety, and a polyethylene-glycol linker. We hypothesised that peptide receptor radionuclide therapy (PRRT) is more effective with [177Lu]Lu-LNC1010 than with [177Lu]Lu-DOTATATE in treating metastatic NPC. METHODS: We assessed binding characteristics of LNC1010 in vitro using C666-1 NPC cells and in-vivo pharmacokinetics of [68Ga]Ga/[177Lu]Lu-LNC1010 in C666-1 NPC xenografts via PET and SPECT imaging, biodistribution studies, and PRRT, and compared them with [68Ga]Ga/[177Lu] Lu-labelled DOTATATE. Furthermore, a proof-of-concept approach for imaging and therapy was conducted in a patient with metastatic NPC. RESULTS: LNC1010 exhibited strong uptake and specific affinity for SSTR2 in C666-1 NPC cells. PET and SPECT imaging demonstrated higher uptake and longer tumour retention of [68Ga]Ga/[177Lu]Lu-LNC1010 than [68Ga]Ga/[177Lu]Lu-DOTATATE in C666-1 NPC xenografts, indicating its suitability for PRRT applications in NPCs. Biodistribution studies confirmed the higher uptake and prolonged retention of [177Lu]Lu-LNC1010 than [177Lu]Lu-DOTATATE. In preclinical PRRT studies, [177Lu]Lu-LNC1010 showed greater inhibition of tumour growth in C666-1 NPC xenografts than [177Lu]Lu-DOTATATE. In a subsequent pilot clinical study, PRRT with [177Lu]Lu-LNC1010 achieved favourable therapeutic and negligible side effects in a patient with metastatic NPC. CONCLUSION: [177Lu]Lu-LNC1010 demonstrated increased tumour uptake and prolonged retention in SSTR2-positive NPCs, with superior anti-tumour efficacy to that of [177Lu]Lu-DOTATATE in preclinical studies. These findings suggest that PRRT with [177Lu]Lu-LNC1010 is a promising treatment for advanced NPC, extending the clinical scope of PRRT beyond neuroendocrine tumours.
引用
- Chen J, Pang Y, Liao X, et al. Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2024. PMID: 39145784. doi:10.1007/s00259-024-06874-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。